ATE169640T1 - Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore - Google Patents

Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore

Info

Publication number
ATE169640T1
ATE169640T1 AT91919512T AT91919512T ATE169640T1 AT E169640 T1 ATE169640 T1 AT E169640T1 AT 91919512 T AT91919512 T AT 91919512T AT 91919512 T AT91919512 T AT 91919512T AT E169640 T1 ATE169640 T1 AT E169640T1
Authority
AT
Austria
Prior art keywords
polypeptide
prevention
treatment
antibody
malignant tumors
Prior art date
Application number
AT91919512T
Other languages
English (en)
Inventor
Pierre Chambon
Marie-Paule Kieny
Richard Lathe
Mara Hareuveni
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE169640T1 publication Critical patent/ATE169640T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT91919512T 1990-10-23 1991-10-23 Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore ATE169640T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9013101A FR2668064B1 (fr) 1990-10-23 1990-10-23 Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.

Publications (1)

Publication Number Publication Date
ATE169640T1 true ATE169640T1 (de) 1998-08-15

Family

ID=9401474

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91919512T ATE169640T1 (de) 1990-10-23 1991-10-23 Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore

Country Status (12)

Country Link
US (3) US5861381A (de)
EP (1) EP0554344B1 (de)
JP (1) JP3195958B2 (de)
AT (1) ATE169640T1 (de)
CA (1) CA2094705C (de)
DE (1) DE69129989T2 (de)
DK (1) DK0554344T3 (de)
ES (1) ES2121791T3 (de)
FR (1) FR2668064B1 (de)
HK (1) HK1012841A1 (de)
SG (1) SG96535A1 (de)
WO (1) WO1992007000A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
ATE152915T1 (de) * 1991-11-29 1997-05-15 Viagene Inc Immuntherapeutische vektorkonstrukte gegen krebs
FR2751343B1 (fr) * 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
US20040033230A1 (en) * 1997-12-24 2004-02-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
WO2000026340A2 (en) * 1998-11-03 2000-05-11 The Penn State Research Foundation Novel nucleic acid molecules encoding opioid growth factor receptors
US7598226B2 (en) * 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6969518B2 (en) * 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
DE19917195B4 (de) * 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
WO2001018035A2 (en) * 1999-09-08 2001-03-15 Transgene S.A. Muc-1 derived peptides
EP1248800A2 (de) * 1999-11-30 2002-10-16 Corixa Corporation Kompositionen und methoden zur therapie und diagnose von brustkrebs
WO2002022685A2 (en) * 2000-09-11 2002-03-21 Kufe Donald W Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
US20040018181A1 (en) * 2000-09-11 2004-01-29 KUFE Donald W. MUC1 interference RNA compositions and methods derived therefrom
JP4564714B2 (ja) 2000-11-27 2010-10-20 ミナーヴァ・バイオテクノロジーズ・コーポレーション 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法
US20020110841A1 (en) * 2000-12-22 2002-08-15 KUFE Donald W. Regulation of cell growth by MUC1
WO2002078607A2 (en) 2001-04-02 2002-10-10 The University Of Miami Mucin peptide with immunoenhancing properties
US6716627B2 (en) 2001-12-20 2004-04-06 Isis Pharmaceuticals, Inc. Antisense modulation of mucin 1, transmembrane expression
JP3854905B2 (ja) * 2002-07-30 2006-12-06 株式会社 日立ディスプレイズ 液晶表示装置
CA2537263C (en) * 2002-11-27 2017-05-30 Minerva Biotechnologies Corporation Techniques and compositions for the diagnosis and treatment of cancer (muc1)
US20080090770A1 (en) * 2003-04-11 2008-04-17 Belmares Michael P Modulation of Muc1 Mediated Signal Transduction
WO2005014642A2 (en) 2003-07-21 2005-02-17 Transgene S.A. Novel multifunctional cytokines
US8129506B2 (en) 2003-10-24 2012-03-06 Genzyme Corporation Modulation of the interaction of MUC1 with MUC1 ligands
EP1697399B1 (de) * 2003-12-12 2016-11-23 GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS Epitop humaner zytotoxischer t-lymphozyten und dessen agonistenepitop aus der nichtvariablen zahl der tandem-wiederholungssequenz von muc-1
WO2005082458A1 (en) * 2004-02-23 2005-09-09 Genzyme Corporation Muc1 antagonist enhancement of death receptor ligand-induced apoptosis
WO2008011672A1 (en) * 2006-07-25 2008-01-31 4G Vaccines Pty Ltd A cancer vaccine comprising a mucin 1 (muc1) t cell epitope-derived peptide
US7871784B2 (en) * 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
EP2387414A1 (de) 2009-01-13 2011-11-23 Transgene SA Verwendung einer saccharomyces cerevisiae mitochondrialen nukleinsäuren-fraktion zur immunstimulation
NZ593749A (en) 2009-01-20 2012-05-25 Transgene Sa Soluble icam-1 as biomarker for prediction of therapeutic response
US20120028279A1 (en) 2009-03-24 2012-02-02 Bruce Acres Biomarker for monitoring patients
BRPI1010512A2 (pt) 2009-04-17 2016-03-15 Transgène S A "método ex vivo para avaliar a eficácia de um tratamento envolvendo a administração de uma composição imunogênica a um paciente, e, uso de níveis de linfócitos t ativados (cd3 + cd69+) como um biomarcador"
CN102740881A (zh) 2009-05-12 2012-10-17 特兰斯吉恩股份有限公司 正痘病毒产生和纯化方法
DK2452194T3 (en) 2009-07-10 2015-11-30 Transgene Sa Biomarker PATIENT SELECTION AND RELATED PRACTICES
TW201109440A (en) 2009-07-21 2011-03-16 Transgene Sa Enzymatic composition for the digestion of chicken embryos
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
WO2014066443A1 (en) 2012-10-23 2014-05-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
WO2016087457A1 (en) 2014-12-01 2016-06-09 Transgene Sa Stable liquid vaccinia virus formulations
CA2976089A1 (en) 2015-02-10 2016-08-18 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
EP3762020A1 (de) 2018-03-07 2021-01-13 Transgene Parapoxvirusvektoren

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707438A (en) * 1984-08-22 1987-11-17 Tel Aviv University Immunoassay for breast cancer employing monoclonal antibodies
ATE160361T1 (de) * 1987-01-07 1997-12-15 Imp Cancer Res Tech Humane polymorphe epitheliale mucin polypeptide zur verwendung in therapie und diagnose
DE10399031I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
SE459115B (sv) * 1987-10-08 1989-06-05 Gas Control Equipment Ab Anordning i ventil foer gasbehaallare
WO1990005142A1 (en) * 1988-11-10 1990-05-17 Imperial Cancer Research Technology Ltd. Polypeptides
JPH02273195A (ja) * 1988-11-17 1990-11-07 Univ Melbourne ヒト多型性上皮ムチンと反応するモノクローナル抗体
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.

Also Published As

Publication number Publication date
US5861381A (en) 1999-01-19
EP0554344B1 (de) 1998-08-12
SG96535A1 (en) 2003-06-16
FR2668064A1 (fr) 1992-04-24
CA2094705A1 (fr) 1992-04-24
WO1992007000A1 (fr) 1992-04-30
DE69129989T2 (de) 1999-04-08
US6328956B1 (en) 2001-12-11
ES2121791T3 (es) 1998-12-16
DK0554344T3 (da) 1999-05-17
JP3195958B2 (ja) 2001-08-06
HK1012841A1 (en) 1999-08-06
CA2094705C (fr) 2007-05-15
US6203795B1 (en) 2001-03-20
EP0554344A1 (de) 1993-08-11
FR2668064B1 (fr) 1994-12-16
DE69129989D1 (de) 1998-09-17
JPH06502399A (ja) 1994-03-17

Similar Documents

Publication Publication Date Title
ATE169640T1 (de) Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore
NO913211D0 (no) Nytt monoklonalt antistoff mot nytt antigen knyttet til menneske-tumorer.
DE68925226D1 (de) Monoklonale Antikörper
RU2008128244A (ru) Способы идентификации опухолей, восприимчивых к лечению антителами против erbb2
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
AU7690596A (en) Anti-CD6 monoclonal antibodies and their uses
Hauck et al. Control of carcinoembryonic antigen gene family expression in a differentiating colon carcinoma cell line, Caco-2
NZ219338A (en) Monoclonal antibody to non-small cell lung carcinoma, its use, production and antigen
GB2278357B (en) Humanised antibodies directed against A33 antigen
PT812206E (pt) Proteina de ligacao a cd40 para estimulacao de uma resposta imunitaria
IL187595A (en) Pharmaceutical preparation containing monoclonal antibody - tumors and production
ES8704082A1 (es) Procedimiento para preparar un agente terapeutico a base de celulas tumorales humanas y eventualmente, neuraminidasa.
CA2308007A1 (en) Enhancer for antibody to lymphocytic tumors
DE69019410D1 (de) Retinoblastoma-Genprodukt-Antikörper und deren Verwendungen.
ES8600518A1 (es) Metodo in vitro para detectar un estado maligno en un paciente humano.
AU5752490A (en) A novel tumor associated antigen
AU5790390A (en) A novel tumor associated antigen
ATE95426T1 (de) Humanes karcinom-assoziertes antigen und an dieses antigen bindende antikoerper.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time